Stocks & Investing
Tue, October 1, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 13, 2024
[ 12:00 AM ] - WOPRAI
Mon, July 29, 2024
[ 12:00 AM ] - WOPRAI
Thu, July 11, 2024
[ 12:00 AM ] - WOPRAI
Mon, June 24, 2024
[ 12:00 AM ] - WOPRAI
Fri, June 21, 2024
[ 12:00 AM ] - WOPRAI
Tue, June 18, 2024
[ 12:00 AM ] - WOPRAI
Tue, May 28, 2024
[ 12:00 AM ] - WOPRAI
Fri, April 26, 2024
[ 12:00 AM ] - WOPRAI
Thu, November 30, 2023
[ 12:00 AM ] - WOPRAI
Fri, November 10, 2023
[ 12:00 AM ] - WOPRAI
Wed, November 8, 2023
[ 12:00 AM ] - WOPRAI
Tue, November 7, 2023
[ 12:00 AM ] - WOPRAI
Thu, November 2, 2023
[ 12:00 AM ] - WOPRAI
Wed, November 1, 2023
[ 12:00 AM ] - WOPRAI
Tue, October 31, 2023
[ 12:00 AM ] - WOPRAI
Wed, October 11, 2023
[ 12:00 AM ] - WOPRAI
Mon, October 9, 2023
[ 12:00 AM ] - WOPRAI
Tue, September 5, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 29, 2023
[ 12:00 AM ] - WOPRAI
Thu, August 10, 2023
[ 12:00 AM ] - WOPRAI
Mon, August 7, 2023
[ 12:00 AM ] - WOPRAI
Thu, August 3, 2023
[ 12:00 AM ] - WOPRAI
Wed, August 2, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 1, 2023
[ 12:00 AM ] - WOPRAI
Fri, July 28, 2023
[ 12:00 AM ] - WOPRAI
Wed, July 26, 2023
[ 12:00 AM ] - WOPRAI
Thu, July 20, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, July 14, 2023 Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $474 on, Oct 1st, 2024
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $462 to $474 on, Oct 1st, 2024.
Matthew has made no other calls on VRTX in the last 4 months.
There are 15 other peers that have a rating on VRTX. Out of the 15 peers that are also analyzing VRTX, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Reiterated at Hold and Held Target at $431 on, Thursday, September 19th, 2024
- Gena Wang of "Barclays" Downgraded from Buy to Hold and Increased Target to $509 on, Monday, August 5th, 2024
- Joseph Stringer of "Needham" Reiterated at Hold on, Friday, July 26th, 2024
These are the ratings of the 12 analyists that currently disagree with Matthew
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $550 on, Monday, August 5th, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $510 on, Monday, August 5th, 2024
- Joon Lee of "Truist Securities" Reiterated at Strong Buy with Increased Target to $550 on, Monday, August 5th, 2024
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $600 on, Monday, August 5th, 2024
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $480 on, Friday, August 2nd, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $535 on, Friday, August 2nd, 2024
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $558 on, Friday, August 2nd, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Strong Sell with Increased Target to $376 on, Wednesday, July 31st, 2024
- Phil Nadeau of "TD Cowen" Maintained at Strong Buy with Increased Target to $500 on, Tuesday, July 23rd, 2024
- Steve Chesney of "Redburn Atlantic" Initiated at Strong Buy and Held Target at $545 on, Thursday, June 27th, 2024
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $555 on, Monday, June 24th, 2024
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $550 on, Monday, June 17th, 2024
